Literature DB >> 15682309

Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine.

Hyun-Sang Cho1, Deepak C D'Souza, Ralitza Gueorguieva, Edward B Perry, Steven Madonick, Laurence P Karper, Anissa Abi-Dargham, Aysenil Belger, Walid Abi-Saab, Deborah Lipschitz, Alexandre Bennet, John P Seibyl, John H Krystal.   

Abstract

RATIONALE: Sensitization to the effects of N-methyl-D-aspartate (NMDA) glutamate receptor antagonists is robust in animals. However, the applicability of this model to humans is unclear because it currently rests on highly confounded retrospective studies of individuals who experienced protracted psychoses following repeated binges with NMDA receptor antagonists.
OBJECTIVES: The purpose of the current study was to determine whether there was evidence of sensitization to the behavioral effects of ketamine in healthy human subjects with repeated exposure to this drug.
METHODS: Data were studied from 295 healthy human subjects who participated in one or more of 11 separate studies that involved ketamine administration over 14 years. Positive and negative symptoms (Brief Psychiatric Rating Scale: BPRS), perceptual alterations (Clinician-Administered Dissociative States Scale: CADSS), and "high" and "anxiety" states (Visual Analog Scale: VAS) that were measured in all studies were included as outcome measures.
RESULTS: After including the number of previous exposures, number of previous studies, and time since first exposure as variables, repeated exposure to ketamine did not result in increased behavioral responses, suggestive of behavioral sensitization.
CONCLUSIONS: The current data do not provide evidence that repeated exposure to ketamine, albeit limited, is associated with sensitization to the behavioral effects of ketamine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15682309     DOI: 10.1007/s00213-004-2066-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  67 in total

Review 1.  Symptom provocation studies in psychiatric disorders: scientific value, risks, and future.

Authors:  D C D'Souza; R M Berman; J H Krystal; D S Charney
Journal:  Biol Psychiatry       Date:  1999-10-15       Impact factor: 13.382

2.  The schizophrenia ketamine challenge study debate.

Authors:  W T Carpenter
Journal:  Biol Psychiatry       Date:  1999-10-15       Impact factor: 13.382

Review 3.  Incentive-sensitization and addiction.

Authors:  T E Robinson; K C Berridge
Journal:  Addiction       Date:  2001-01       Impact factor: 6.526

4.  Study of potency, kinetics of block and toxicity of NMDA receptor antagonists using fura-2.

Authors:  M Black; T Lanthorn; D Small; G Mealing; V Lam; P Morley
Journal:  Eur J Pharmacol       Date:  1996-12-19       Impact factor: 4.432

5.  Long-term dangers of ketamine anaesthesia.

Authors:  B B Collier
Journal:  Br J Anaesth       Date:  1981-05       Impact factor: 9.166

6.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

7.  Chlorpromazine vs. meperidine in the treatment of phencyclidine psychosis.

Authors:  A J Giannini; R H Loiselle; W A Price; M C Giannini
Journal:  J Clin Psychiatry       Date:  1985-02       Impact factor: 4.384

Review 8.  NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.

Authors:  J H Krystal; D C D'Souza; I L Petrakis; A Belger; R M Berman; D S Charney; W Abi-Saab; S Madonick
Journal:  Harv Rev Psychiatry       Date:  1999 Sep-Oct       Impact factor: 3.732

9.  Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia.

Authors:  P Klepstad; P C Borchgrevink
Journal:  Acta Anaesthesiol Scand       Date:  1997-03       Impact factor: 2.105

10.  Patterns of use and harms associated with non-medical ketamine use.

Authors:  Paul Dillon; Jan Copeland; Karl Jansen
Journal:  Drug Alcohol Depend       Date:  2003-01-24       Impact factor: 4.492

View more
  16 in total

Review 1.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 2.  Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.

Authors:  Marc S Lener; Bashkim Kadriu; Carlos A Zarate
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

3.  Greater vulnerability to the amnestic effects of ketamine in males.

Authors:  Celia J A Morgan; Edward B Perry; Hyung-Sang Cho; John H Krystal; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2006-08-01       Impact factor: 4.530

Review 4.  Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.

Authors:  Nurith Amitai; Athina Markou
Journal:  Biol Psychiatry       Date:  2010-05-21       Impact factor: 13.382

5.  Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims.

Authors:  Michael Schönenberg; Ursula Reichwald; Gregor Domes; Andreas Badke; Martin Hautzinger
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 6.  Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.

Authors:  Weili Zhu; Zengbo Ding; Yinan Zhang; Jie Shi; Kenji Hashimoto; Lin Lu
Journal:  Neurosci Bull       Date:  2016-11-22       Impact factor: 5.203

7.  Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats.

Authors:  Nurith Amitai; Ronald Kuczenski; M Margarita Behrens; Athina Markou
Journal:  Neuropharmacology       Date:  2011-01-14       Impact factor: 5.250

8.  Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats.

Authors:  Eric M Parise; Lyonna F Alcantara; Brandon L Warren; Katherine N Wright; Roey Hadad; Omar K Sial; Kyle G Kroeck; Sergio D Iñiguez; Carlos A Bolaños-Guzmán
Journal:  Biol Psychiatry       Date:  2013-06-19       Impact factor: 13.382

Review 9.  Preclinical models of antipsychotic drug action.

Authors:  José L Moreno; Javier González-Maeso
Journal:  Int J Neuropsychopharmacol       Date:  2013-06-10       Impact factor: 5.176

10.  Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.

Authors:  Luli Akinfiresoye; Yousef Tizabi
Journal:  Psychopharmacology (Berl)       Date:  2013-06-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.